BLCM Share Price Performance
US$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
BLCM Community Narratives
There are no narratives available yet.
Bellicum Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Sep 30, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.90
- Gross Margin
- -1,135.08%
- Net Profit Margin
- -1,483.95%
- Debt/Equity Ratio
- 0%
Bellicum Pharmaceuticals, Inc. Competitors
This week, we’re going to look at the U.S. regulatory changes, how adoption has been trending, and one of the risks with the ETFs. If you want some exposure to Bitcoin, at the end, we’ll show you some different ways you can position your portfolio accordingly.
Continue reading
About BLCM
- Founded
- 2004
- Employees
- 13
- CEO
- WebsiteView website
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company’s clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
U.S. Market Performance
- 7 Days: 1.3%
- 3 Months: 8.8%
- 1 Year: 15.8%
- Year to Date: 9.5%
The Healthcare and Consumer Discretionary sectors drove a 1.3% in the market over the last week. As for the past 12 months, the market is up 16%. Earnings are forecast to grow by 15% annually. Market details ›